title: Effects of pioglitazone on survival and omental adipocyte function in mice with sepsis induced by cecal ligation and puncture.
abstract: BACKGROUND
  To examine the effects of pioglitazone, peroxisome proliferator-activated receptor-gamma (PPAR-γ), on mortality and omental adipocyte function in mice with cecal ligation and puncture (CLP).
  
  
  METHODS
  Male mice were assigned to receive (1) vehicle/sham-operation, (2) pioglitazone/CLP, or (3) vehicle/CLP. Pioglitazone was injected intraperitoneally for 7 d before operation. Serum and omental tissue were collected before, 24, and 48 h after CLP. Serum levels of adiponectin, cytokine, and chemokine were measured with ELISA. mRNA expressions in omental tissues were determined by RT-PCR. Survival was monitored for 7 d after CLP.
  
  
  RESULTS
  Survival after CLP was significantly better in the pioglitazone/CLP than in the vehicle/CLP. Serum adiponectin levels before CLP were higher in the pioglitazone/CLP than in the vehicle/CLP. Treatment with pioglitazone significantly inhibited the increases in the serum interleukin-6 and monocyte chemoattractant protein-1 (MCP-1) levels after CLP and lowered the mRNA expressions of proinflammatory cytokines, interleukin-6, and MCP-1 in omental tissue after CLP.
  
  
  CONCLUSIONS
  The anti-inflammatory effects of pioglitazone on omental adipocyte function appear to be mediated in part by PPAR-γ activation, which down-regulates the production of inflammatory mediators.
authors.affiliation: Department of Endocrine Pharmacology, Tokyo University of Pharmacy and Life Sciences, Horinouchi, Hachioji, Tokyo, Japan.
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Tsujimura
authors.forename: Takeshi
authors.initials: T
authors.lastname: Matsutani
authors.forename: Akihisa
authors.initials: A
authors.lastname: Matsuda
authors.forename: Masahiko
authors.initials: M
authors.lastname: Kutsukake
authors.forename: Eiji
authors.initials: E
authors.lastname: Uchida
authors.forename: Koji
authors.initials: K
authors.lastname: Sasajima
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Tamura
mesh_terms: D017667:Adipocytes / Q000187:drug effects* / Q000502:physiology; D052242:Adiponectin / Q000097:blood / Q000235:genetics; D000818:Animals; D002432:Cecum / Q000293:injuries*; D018932:Chemokine CCL2 / Q000097:blood / Q000235:genetics; D004195:Disease Models, Animal; D015870:Gene Expression / Q000276:immunology; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D015850:Interleukin-6 / Q000097:blood / Q000235:genetics; D008026:Ligation; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009852:Omentum / Q000166:cytology / Q000276:immunology; D010538:Peritonitis / Q000188:drug therapy / Q000276:immunology / Q000401:mortality; D000077205:Pioglitazone; D018805:Sepsis / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D045162:Thiazolidinediones / Q000494:pharmacology*; D014951:Wounds, Stab / Q000276:immunology
chemical_list: D052242:Adiponectin; C499919:Adipoq protein, mouse; C491768:Ccl2 protein, mouse; D018932:Chemokine CCL2; D007004:Hypoglycemic Agents; D015850:Interleukin-6; D045162:Thiazolidinediones; D000077205:Pioglitazone